SCHOTT Pharma’s AGM Sees Strong Shareholder Support and Announces Continued Growth Plans

SCHOTT Pharma’s AGM Sees Strong Shareholder Support and Announces Continued Growth Plans

(IN BRIEF) SCHOTT Pharma’s AGM on February 4, 2025, revealed strong fiscal results for FY 2024, including exceeding revenue targets and a promotion to the MDAX. Shareholders approved all agenda items, including the appointment of Dr. Wolfram Carius to the Supervisory Board and the declaration of a dividend. CEO Andreas Reisse emphasized continued profitable growth, while the company strengthened its commitment to high-value pharma solutions.

(PRESS RELEASE) MAINZ, 5-Feb-2025 — /EuropaWire/ — SCHOTT Pharma held a successful Annual General Meeting (AGM) on February 4, 2025, where all items on the agenda were approved by shareholders. The meeting, conducted virtually, allowed shareholders to interact with the Management and Supervisory Boards, reflecting on the strong performance of the fiscal year 2024. SCHOTT Pharma exceeded its targets, including its raised revenue guidance, and celebrated its first year as a publicly listed company with a promotion to the MDAX.

During the meeting, shareholders voted in favor of several key decisions, including the appointment of Dr. Wolfram Carius to the Supervisory Board, replacing Dr. Wolfgang Wienand. Dr. Carius, Executive Vice President of Bayer AG, brings extensive expertise in the pharma industry. The company also confirmed its commitment to its strategic shift toward high-value solutions, highlighting the growth opportunities in areas such as GLP-1 and mRNA drugs, ADCs, and homecare solutions.

CEO Andreas Reisse spoke about the company’s continued growth trajectory, bolstered by a strong global market position and a commitment to providing innovative products. CFO Dr. Almuth Steinkühler highlighted SCHOTT Pharma’s profitability, announcing a dividend payout of EUR 0.16 per share to shareholders.

The meeting saw overwhelming approval from shareholders, with significant votes in favor of the financial statements, profit allocation, and the election of KPMG as the new auditor. The approval of the actions of the Executive and Supervisory Boards was also achieved by a large majority, reflecting the strong confidence of the shareholders in the company’s leadership.

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the MDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com

Media Contact:

Lea Kaiser
PR & Communications Manager
+49 (0) 6131 66-2422

SOURCE: SCHOTT Pharma